The Journal of Practical Medicine ›› 2024, Vol. 40 ›› Issue (17): 2425-2429.doi: 10.3969/j.issn.1006-5725.2024.17.012

• Clinical Research • Previous Articles     Next Articles

Clinical value of serum VILIP⁃1 and Hepc25 in predicting prognosis of patients with acute ischemic stroke after intravenous thrombolysis

Yan LI1,Xianlong XIE2(),Mengli ZHU1,Qing. SU1   

  1. *.Department of Emergency Medicine,the First Hospital of Wuhan,Wuhan 430022,China
  • Received:2024-03-28 Online:2024-09-10 Published:2024-09-13
  • Contact: Xianlong XIE E-mail:xiexianlong12345@163.com

Abstract:

Objective The clinical value of serum VILIP-1 and Hepc25 in predicting the prognosis of patients with Acute ischemic stroke (AIS) from intravenous thrombolysis was analyzed. Methods A total of 225 patients with acute ischemic stroke diagnosed and treated in the hospital from January 2022 to November 2023 were selected. According to Rankin Scale (mRS) grouping study, 97 patients with mRS ≥ 3 were divided into poor prognosis group and 128 patients with mRS < 3 were divided into good prognosis group. The serum levels of VILIP-1 and Hepc25 were compared and their prognostic value for intravenous thrombolysis. Results After logistic regression analysis, age, admission blood glucose, LYM, NIHSS score, PLT, WBC, VILIP-1, and Hepc25 were all factors affecting the prognosis of AIS patients (P < 0.05); VILIP-1 and Hepc25 levels increased in patients with moderate and severe defects compared with mild defects. VILIP-1 and Hepc25 levels were higher in patients with severe defects than those with moderate defects. Compared with the poor prognosis group, the VILIP-1 and Hepc25 levels in the good prognosis group were decreased, with statistical difference (P < 0.05). ROC curve analysis showed that single diagnosis of VILIP-1 and Hepc25 was lower than combined diagnosis (P < 0.05). Conclusion The elevated levels of VILIP-1 and Hepc25 participate in the process of intravenous thrombolysis and affect the prognosis of patients, and can be used as clinical indicators for the prognosis of AIS patients.

Key words: serum VILIP-1, Hepc25, acute ischemic stroke, intravenous thrombolysis

CLC Number: